

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



撥康視云™

Cloudbreak Pharma

CLOUDBREAK PHARMA INC.

撥康視雲製藥有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2592)

**FORMATION OF AN INDEPENDENT SPECIAL COMMITTEE;
DELAY IN PUBLICATION AND DESPATCH OF 2026 INTERIM REPORT;
AND
CONTINUED SUSPENSION OF TRADING**

This announcement is made by Cloudbreak Pharma Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Formation of an Independent Special Committee

Reference is made to the announcements of the Company dated 18 September 2026 and 23 September 2026 in relation to the suspension of trading and the potential formation of an independent special committee, respectively (the “**Announcements**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to announce that, on 30 September 2026, the Board resolved to form an Independent Special Committee comprising Mr. Chan Sheung Yan Andrew and Mr. Kwai Sze Kit, each being an independent non-executive Director appointed on 23 September 2026, to undertake and supervise an internal investigation in relation to the Commission’s concerns (the “**Internal Investigation**”) and to carry out any necessary related matters in accordance with the Announcement of the Company dated 23 September 2026. To ensure complete impartiality and bolster public confidence, the Independent Special Committee consists of these newly appointed independent non-executive Directors. The Company will update its shareholders and potential investors regarding the results of the Internal Investigation as and when appropriate.

Delay in Publication and Despatch of the 2026 Interim Report

Pursuant to Rule 13.48(1) of the Listing Rules, the Company is required to despatch its interim report for the six months ended 30 June 2026 (the “**2026 Interim Report**”) to its shareholders not later than three months after the end of that period of six months, i.e. on or before 30 September 2026.

As additional time is required to complete the Internal Investigation and finalise the contents of the 2026 Interim Report, the Company will not be able to publish and despatch it by 30 September 2026. The Company shall use its best endeavours to issue the 2026 Interim Report as soon as possible. Further announcement(s) in relation to the update of the publication of the 2026 Interim Report will be made by the Company as and when appropriate in accordance with the Listing Rules.

Continued Suspension of Trading

All dealings in the shares of the Company have been suspended by the Stock Exchange as directed by the Commission since 9:00 a.m. on 10 September 2026 and will remain suspended until further notice.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board
Cloudbreak Pharma Inc.
Dr. NI Jinsong

Chairman, Executive Director and Chief Executive Officer

Hong Kong, 30 September 2026

As at the date of this announcement, the Board comprises: (i) Dr. Ni Jinsong, Mr. Dinh Son Van and Dr. Yang Rong as executive directors; (ii) Dr. Li Jun Zhi, Mr. Cao Xu and Mr. Xia Zhidong as non-executive directors; and (iii) Ms. Nie Sijiang, Mr. Ma Yiu Ho Peter, Mr. Lee Alex Jao Jang, Mr. Chan Sheung Yan Andrew and Mr. Kwai Sze Kit as independent non-executive directors.

* *For identification purposes only*